• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Lentigo Maligna Melanoma, In Situ

Article

The development of eccentric pigmentation within a previously stable pigmented lesion may indicate malignant degeneration, as was the case here. Of all melanomas, lentigo maligna melanoma has the best overall prognosis.

An 82-year-old man complained about an asymptomatic “spot” on his chest within which a darker area had recently developed.

Key point: Physical examination revealed a large pigmented macule on the right upper chest. A darker area was eccentrically placed within the larger lesion. A biopsy revealed lentigo maligna melanoma, in situ.

Treatment: The lesion was removed by simple excision with a 5-mm border of normal skin.

Note: The development of eccentric pigmentation within a heretofore stable pigmented lesion may indicate malignant degeneration. There is some debate about the optimal border of normal skin to remove, with proponents of anywhere from several millimeters to nearly a centimeter. Lentigo maligna melanoma has the best overall prognosis among all types of melanomas.

Related Content
Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose

Sydney Jennings
November 7th 2024
Article

Your daily dose of the clinical news you may have missed.

When is It Time to Refer: A Dermatologist Considers Atopic Dermatitis Treated in Primary Care / Image credit Central Connecticut Dermatology

When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care

Grace Halsey
November 7th 2024
Article

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD / image credit Central Connecticut Dermatology

Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD

Grace Halsey
November 6th 2024
Article

They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children / image credit ©Organon

FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children

Grace Halsey
November 5th 2024
Article

The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.

Atopic Dermatitis: Final ADORING 3 Open-Lael Extension Trial Findings with Tapinarof 1% Announced / image credit atopic dermatitis concept ©New Africa/stock.adobe.com

Atopic Dermatitis: Final ADORING 3 Open-Label Extension Trial Findings with Tapinarof Cream, 1% Announced

Grace Halsey
October 31st 2024
Article

Over 80% of participants, (2 to 17 y/o) achieved clear or almost clear skin during the 48-week trial, and treatment-free intervals lasted more than 2 months.

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Dupilumab Efficacy for Severe Atopic Dermatitis Durable at 5 Years: New Data

Ryan Flinn
October 25th 2024
Article

After 60 months of treatment, 38% of study participants with severe AD achieved complete remission.

© 2024 MJH Life Sciences

All rights reserved.